KR102273481B1 - 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법 - Google Patents

사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법 Download PDF

Info

Publication number
KR102273481B1
KR102273481B1 KR1020200113258A KR20200113258A KR102273481B1 KR 102273481 B1 KR102273481 B1 KR 102273481B1 KR 1020200113258 A KR1020200113258 A KR 1020200113258A KR 20200113258 A KR20200113258 A KR 20200113258A KR 102273481 B1 KR102273481 B1 KR 102273481B1
Authority
KR
South Korea
Prior art keywords
nano
castor oil
cyclosporine
less
emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020200113258A
Other languages
English (en)
Korean (ko)
Other versions
KR20210030215A (ko
Inventor
이준엽
신윤재
서현원
김대훈
Original Assignee
주식회사태준제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사태준제약 filed Critical 주식회사태준제약
Publication of KR20210030215A publication Critical patent/KR20210030215A/ko
Priority to KR1020210085410A priority Critical patent/KR102638866B1/ko
Application granted granted Critical
Publication of KR102273481B1 publication Critical patent/KR102273481B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020200113258A 2019-09-09 2020-09-04 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법 Active KR102273481B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020210085410A KR102638866B1 (ko) 2019-09-09 2021-06-30 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190111776 2019-09-09
KR1020190111776 2019-09-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020210085410A Division KR102638866B1 (ko) 2019-09-09 2021-06-30 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법

Publications (2)

Publication Number Publication Date
KR20210030215A KR20210030215A (ko) 2021-03-17
KR102273481B1 true KR102273481B1 (ko) 2021-07-06

Family

ID=74867274

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020200113258A Active KR102273481B1 (ko) 2019-09-09 2020-09-04 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법
KR1020210085410A Active KR102638866B1 (ko) 2019-09-09 2021-06-30 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020210085410A Active KR102638866B1 (ko) 2019-09-09 2021-06-30 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법

Country Status (8)

Country Link
US (1) US12576126B2 (cg-RX-API-DMAC7.html)
EP (1) EP4029493A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022548221A (cg-RX-API-DMAC7.html)
KR (2) KR102273481B1 (cg-RX-API-DMAC7.html)
CN (1) CN114364372A (cg-RX-API-DMAC7.html)
CA (1) CA3149270A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550500A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021049825A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023190283A1 (ja) * 2022-03-28 2023-10-05 中外製薬株式会社 ポリオキシエチレン構造を含む油性成分を含有する化合物製剤
IL294896B1 (en) * 2022-07-20 2026-06-01 LYOTROPIC DELIVERY SYSTEMS Ltd Topical administration of cyclosporine to the eye

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501228A (ja) 2005-07-13 2009-01-15 アラーガン、インコーポレイテッド シクロスポリン組成物
KR101492447B1 (ko) 2013-05-20 2015-02-23 주식회사태준제약 사이클로스포린을 함유하는 나노에멀젼 점안 조성물 및 그의 제조 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635796B2 (en) 1990-03-16 2003-10-21 Sevenson Environmental Services, Inc. Reduction of leachability and solubility of radionuclides and radioactive substances in contaminated soils and materials
KR0167613B1 (ko) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
KR20020011985A (ko) * 1999-05-07 2002-02-09 파르마솔 게엠베하 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법
CA2426164C (en) 2001-06-27 2009-08-11 Nokia Corporation Method and system for bearer authorization in a wireless communication network
AU2002357604A1 (en) 2001-12-21 2003-07-09 Senju Pharmaceutical Co., Ltd. Eye drops
PT1487416E (pt) 2002-03-26 2010-01-25 Teva Pharma Micropartículas de fármacos
CN1232539C (zh) 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
AU2004212989A1 (en) * 2003-02-20 2004-09-02 Teva Pharmaceutical Industries Ltd. Menthol solutions of drugs
US20070008894A1 (en) 2004-10-19 2007-01-11 Idt Corporation Telecommunications-based link monitoring system
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
KR100669510B1 (ko) 2005-08-17 2007-01-16 보람제약주식회사 사이크로스포린을 함유한 나노 에멀젼 농축액 조성물 및 그제조방법
CN101244256A (zh) * 2007-02-16 2008-08-20 中国科学院上海药物研究所 一种环孢菌素a眼用微/亚微乳原位凝胶制剂及其制备方法
EP3078385A1 (en) * 2010-05-25 2016-10-12 Allergan, Inc. Cyclosporin emulsions
WO2012015211A2 (ko) * 2010-07-30 2012-02-02 주식회사종근당 사이클로스포린 에이 함유 점안제 조성물
KR20130100290A (ko) * 2010-08-30 2013-09-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 협착성 병변을 위한 전단 제어 방출 및 혈전 용해 치료법
US8455991B2 (en) 2010-09-24 2013-06-04 Stats Chippac Ltd. Integrated circuit packaging system with warpage control and method of manufacture thereof
WO2013008714A1 (ja) * 2011-07-08 2013-01-17 ロート製薬株式会社 眼科用水性組成物
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
US10963928B2 (en) 2014-08-21 2021-03-30 Stubhub, Inc. Crowdsourcing seat quality in a venue
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
KR20170032808A (ko) * 2015-09-15 2017-03-23 주식회사 엘지생활건강 멘톨 또는 멘톨 유도체를 포함하는 용해성 미세바늘 패치
CN105726479B (zh) * 2016-03-24 2018-06-22 北京茗泽中和药物研究有限公司 环孢素眼用乳剂
CA3285799A1 (en) * 2016-10-12 2025-11-29 Ps Therapy, Inc. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
US11583496B2 (en) * 2016-10-12 2023-02-21 PS Therapy Inc. Drug vehicle compositions and methods of use thereof
WO2019111917A1 (ja) * 2017-12-07 2019-06-13 ライオン株式会社 水性眼科用組成物及びエマルション粒子の微粒化方法
CN110090294A (zh) * 2019-04-09 2019-08-06 嘉兴市爵拓科技有限公司 具有改善的干燥保护和保留的眼用组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501228A (ja) 2005-07-13 2009-01-15 アラーガン、インコーポレイテッド シクロスポリン組成物
KR101492447B1 (ko) 2013-05-20 2015-02-23 주식회사태준제약 사이클로스포린을 함유하는 나노에멀젼 점안 조성물 및 그의 제조 방법

Also Published As

Publication number Publication date
EP4029493A4 (en) 2023-10-04
CN114364372A (zh) 2022-04-15
KR20210030215A (ko) 2021-03-17
WO2021049825A1 (ko) 2021-03-18
KR102638866B1 (ko) 2024-02-21
KR20210084389A (ko) 2021-07-07
EP4029493A1 (en) 2022-07-20
PH12022550500A1 (en) 2023-10-18
US20240041974A1 (en) 2024-02-08
JP2022548221A (ja) 2022-11-17
US12576126B2 (en) 2026-03-17
CA3149270A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
KR102204221B1 (ko) 사이클로스포린을 함유하는 나노에멀젼 점안 조성물 및 그의 제조 방법
EP2136782B1 (en) Ophthalmic oil-in-water emulsions containing prostaglandins
JP5441058B2 (ja) 四級アンモニウム化合物を含む組成物
EP2968139B1 (en) Microemulsion topical delivery platform
WO2023103835A1 (zh) 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途
WO2021032073A1 (en) In-situ gel containing cyclosporine micelles as sustained ophthalmic drug delivery system
KR102638866B1 (ko) 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법
RU2698456C2 (ru) Офтальмологический гель биматопроста, который наносится в виде капель
WO2018105681A1 (ja) 眼科用組成物及びその製造方法
KR20150000405A (ko) 난용성 의약품의 수중유적형 에멀젼 조성물 및 이의 제조방법
JP2002506808A (ja) グリコーゲン含有眼用溶液
CN110022856B (zh) 用于降低眼压的眼用组合物
DK3229780T3 (en) Ophthalmic composition for use in the treatment of dry eye syndrome
CN112839641A (zh) 眼科用组合物
RU2634267C2 (ru) Водный офтальмологический раствор на основе циклоспорина a
KR101510764B1 (ko) 사이클로스포린 함유 안약 조성물 및 그 제조방법
TW201836611A (zh) 含有他氟前列素及檸檬酸酯之緩釋劑
US20240009124A1 (en) Ophthalmic Suspension Base having a Micro-fluidized Positively Charged Nanoparticle
JPH0273014A (ja) 眼科用α―メチル―4―(2’―チエニルカルボニル)フェニル酢酸リジン液剤の製法
McCann Advances and challenges in topical ocular medications
HK40005358B (en) Eye-drop composition for lowering intraocular pressure
HK40005358A (en) Eye-drop composition for lowering intraocular pressure
HK1133598B (en) Ophthalmic oil-in-water emulsions containing prostaglandins

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0107 Divisional application

St.27 status event code: A-0-1-A10-A18-div-PA0107

St.27 status event code: A-0-1-A10-A16-div-PA0107

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6